BioMedPartners, a venture capital firm based in Basel, led a $39m Series A round in TOLREMO, a research and product development in Basel, Switzerland, with participation from Pierre Fabre. "TOLREMO has a very distinct scientific approach to providing rational combination therapies that preemptively address the problem of drug resistance in cancer treatment. TT125-802 inhibits transcriptional changes, which are central for resistance development to a multitude of targeted cancer therapies. This new investment is very consistent with our renewed strategy to focus our R&D portfolio on targeted therapies," Francesco Hofmann, Pierre Fabre Laboratories Head of R&D for Medical Care.